19 Jul FibroBiologics
Hamid Khoja, Ph.D., Chief Scientific Officer
Oct.7 | 5:45pm | FLW Ballroom F
Houston, TX
(NASDAQ:FBLG)
FibroBiologics is a clinical stage biotechnology company focused on developing and commercializing fibroblast cell-based therapies for patients suffering from chronic diseases.
Our proprietary fibroblast platform technology serves as the foundation for developing biologic cures and treatments for chronic diseases, including chronic wounds (diabetic foot ulcers), multiple sclerosis, degenerative disc disease, psoriasis, anti-aging extension of life applications such as thymic involution reversal, and cancer. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical indications, including disc degeneration, orthopedics, multiple sclerosis, autoimmune disorders, wound healing, reversing tymus involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy.
